Nivestim (Filgrastim)

Filgrastim, the active ingredient in Nivestim, is a granulocyte colony‑stimulating factor presented as an injectable solution for intravenous and subcutaneous use. It treats chemotherapy‑induced neutropenia, neutropenia following bone‑marrow transplantation, and aids peripheral blood stem cell mobilization.

GNH USA supplies Nivestim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Nivestim, a granulocyte colony‑stimulating factor, is employed to manage neutropenia across several clinical pathways.

Chemotherapy‑induced neutropenia: shortens the duration of low neutrophil counts and reduces infection risk in patients receiving cytotoxic chemotherapy. Neutropenia after bone‑marrow transplantation: accelerates neutrophil recovery post‑transplant, supporting engraftment. Peripheral blood stem cell mobilization: enhances the release of stem cells into peripheral blood for collection prior to autologous transplantation.

Nivestim may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Bone pain: mild to moderate discomfort in the limbs or back. - Injection‑site reactions: redness, swelling, or tenderness at the administration site. - Fever: low‑grade temperature elevations. - Headache: transient mild to moderate headache. - Fatigue: general tiredness or lack of energy. - Nausea: occasional mild gastrointestinal upset.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and signs of internal bleeding. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty and low oxygen levels. - Severe allergic reactions: hives, swelling, or anaphylaxis. - Leukocytosis: excessively high white‑blood‑cell counts. - Capillary leak syndrome: rapid fluid shift causing edema and low blood pressure. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When using Nivestim, several safety considerations should be observed.

Monitor blood counts: regularly assess neutrophil levels to guide therapy. Assess for splenomegaly: evaluate spleen size before and during treatment. Use caution in sickle‑cell disease: increased risk of vaso‑occlusive events. Avoid in known hypersensitivity: discontinue if allergic reactions occur. Adjust in renal impairment: consider reduced clearance in severe dysfunction. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid): - Concurrent use with other G‑CSF agents: risk of excessive neutrophil proliferation. - Cytarabine therapy: may heighten pulmonary toxicity. - High‑dose corticosteroids: potential reduction in filgrastim efficacy.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics: may mask signs of infection. - Immunosuppressants (e.g., cyclosporine): could alter neutrophil response. - Live vaccines: reduced immunogenicity; assess timing relative to filgrastim administration.